Sichuan Kelun Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Sichuan Kelun Pharmaceutical has a total shareholder equity of CN¥26.2B and total debt of CN¥5.2B, which brings its debt-to-equity ratio to 19.7%. Its total assets and total liabilities are CN¥38.4B and CN¥12.2B respectively. Sichuan Kelun Pharmaceutical's EBIT is CN¥4.3B making its interest coverage ratio -40.6. It has cash and short-term investments of CN¥7.1B.
Key information
19.7%
Debt to equity ratio
CN¥5.16b
Debt
Interest coverage ratio | -40.6x |
Cash | CN¥7.08b |
Equity | CN¥26.23b |
Total liabilities | CN¥12.16b |
Total assets | CN¥38.39b |
Recent financial health updates
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?
Jul 12These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely
Feb 27Recent updates
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
Dec 23Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement
Sep 22Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?
Aug 16Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?
Jul 12Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares
Jun 11An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued
May 21Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem
May 02If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity
Mar 19Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Mar 04These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely
Feb 27Financial Position Analysis
Short Term Liabilities: 002422's short term assets (CN¥19.1B) exceed its short term liabilities (CN¥10.1B).
Long Term Liabilities: 002422's short term assets (CN¥19.1B) exceed its long term liabilities (CN¥2.0B).
Debt to Equity History and Analysis
Debt Level: 002422 has more cash than its total debt.
Reducing Debt: 002422's debt to equity ratio has reduced from 78% to 19.7% over the past 5 years.
Debt Coverage: 002422's debt is well covered by operating cash flow (84.6%).
Interest Coverage: 002422 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 19:08 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sichuan Kelun Pharmaceutical Co., Ltd. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Pei Cheng | China Galaxy Securities Co., Ltd. |
Jin Zhang | China International Capital Corporation Limited |
Ziyu He | China International Capital Corporation Limited |